QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NASDAQ:OPRX

OptimizeRx Stock Forecast, Price & News

$94.42
-0.89 (-0.93 %)
(As of 10/27/2021 04:00 PM ET)
Add
Compare
Today's Range
$93.76
$97.00
50-Day Range
$57.68
$87.24
52-Week Range
$19.13
$98.15
Volume
118,249 shs
Average Volume
250,133 shs
Market Capitalization
$1.66 billion
P/E Ratio
786.83
Dividend Yield
N/A
Beta
0.66
30 days | 90 days | 365 days | Advanced Chart
Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.


OptimizeRx logo

About OptimizeRx

OptimizeRx Corp. is digital health company, which engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging; and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:OPRX
Employees
2,018
Year Founded
N/A

Sales & Book Value

Annual Sales
$43.31 million
Cash Flow
$0.18 per share
Book Value
$3.31 per share

Profitability

Net Income
$-2.21 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.66 billion
Next Earnings Date
11/8/2021 (Estimated)
Fiscal Year End
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.08 out of 5 stars

Computer And Technology Sector

367th out of 874 stocks

Business Services, Not Elsewhere Classified Industry

60th out of 134 stocks

Analyst Opinion: 1.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

Is OptimizeRx a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OptimizeRx stock.
View analyst ratings for OptimizeRx
or view top-rated stocks.

What stocks does MarketBeat like better than OptimizeRx?

Wall Street analysts have given OptimizeRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OptimizeRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OptimizeRx?

OptimizeRx saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 1,720,000 shares, an increase of 35.4% from the September 30th total of 1,270,000 shares. Based on an average daily trading volume, of 316,700 shares, the short-interest ratio is currently 5.4 days. Approximately 11.2% of the shares of the company are sold short.
View OptimizeRx's Short Interest
.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for OptimizeRx
.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Wednesday, August, 4th. The company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.02 by $0.08. The company earned $13.63 million during the quarter, compared to the consensus estimate of $12.35 million. OptimizeRx had a trailing twelve-month return on equity of 2.26% and a net margin of 3.98%.
View OptimizeRx's earnings history
.

How has OptimizeRx's stock been impacted by Coronavirus?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPRX stock has increased by 1,157.3% and is now trading at $94.42.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OPRX?

4 brokerages have issued 1-year price objectives for OptimizeRx's stock. Their forecasts range from $54.00 to $102.00. On average, they anticipate OptimizeRx's share price to reach $76.50 in the next year. This suggests that the stock has a possible downside of 19.0%.
View analysts' price targets for OptimizeRx
or view top-rated stocks among Wall Street analysts.

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Will Febbo, Chief Executive Officer & Director
  • Miriam J. Paramore, President & Chief Strategy Officer (LinkedIn Profile)
  • Doug Baker, Chief Financial Officer
  • Todd Inman, Chief Technology Officer
  • Marion K. Odence-Ford, Chief Compliance Officer & General Counsel

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), The Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Calamos Advisors LLC (0.66%), Perkins Capital Management Inc. (0.65%), Cannon Global Investment Management LLC (0.22%), Greenwood Capital Associates LLC (0.14%), Taylor Wealth Management Partners (0.12%) and Hillsdale Investment Management Inc. (0.09%). Company insiders that own OptimizeRx stock include Douglas P Baker, Douglas P Baker, Ellen O'connor Vos, Gregory D Wasson, Gus D Halas, Miriam J Paramore, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends for OptimizeRx
.

Which major investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., Perkins Capital Management Inc., Taylor Wealth Management Partners, and Greenwood Capital Associates LLC. Company insiders that have sold OptimizeRx company stock in the last year include Douglas P Baker, Miriam J Paramore, Stephen L Silvestro, and William J Febbo.
View insider buying and selling activity for OptimizeRx
or view top insider-selling stocks.

Which major investors are buying OptimizeRx stock?

OPRX stock was purchased by a variety of institutional investors in the last quarter, including Cannon Global Investment Management LLC, Calamos Advisors LLC, DORCHESTER WEALTH MANAGEMENT Co, and Robeco Institutional Asset Management B.V.. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, Gregory D Wasson, Gus D Halas, and William J Febbo.
View insider buying and selling activity for OptimizeRx
or or view top insider-buying stocks.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $94.42.

How much money does OptimizeRx make?

OptimizeRx has a market capitalization of $1.66 billion and generates $43.31 million in revenue each year.

How many employees does OptimizeRx have?

OptimizeRx employs 2,018 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

Where are OptimizeRx's headquarters?

OptimizeRx is headquartered at 400 WATER STREET SUITE 200, ROCHESTER MI, 48307.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at (248) 651-6568 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.